Aspirin
Migraine Disorder
Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
Cairo University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
71High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05546320CT.gov Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale | — | Completed | — | — | — |
NCT01973205CT.gov Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine | — | Completed | — | — | — |
NCT01248468CT.gov Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine | — | Completed | — | — | — |
NCT01629329CT.gov Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Migraine Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Aspirin (this asset) | Cairo University | Approved | BBB · 72 |
| Atogepant | Stanford University | P4 | A |
| Naproxen | IRCCS San Raffaele Roma | P4 | A |
| Zolmitriptan | Zosano Pharma Corporation | P4 | A |
| Rizatriptan | Antonios Likourezos | P4 | A |
| Ubrogepant | H. Lundbeck A/S | P4 | BBB |
| Dfn-11 (Sumatriptan Injection) | IRCCS San Raffaele Roma | P4 | BBB |
| Eptinezumab | Stanford University | P4 | BBB |
| Eletriptan | Boehringer Ingelheim | P4 | BBB |
+42 more in the Migraine Disorder cohort
Other indications for Aspirin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myocardial Infarction | — | P4 | A · 83 |
| Coronary Artery Disorder | — | P4 | BBB · 79 |
| Cardiovascular Disorder | — | P4 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Aspirin in Migraine Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/aspirin-migraine-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →